Business

Biocon signs distribution and supply agreement with Medix

For commercialization of the weight management drug – Liraglutide (gSaxenda)

Biocon announced the signing of a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda), used in the treatment of chronic weight management.

Under the terms of this agreement, Biocon will undertake the responsibility of obtaining regulatory approval, manufacturing, and supply of the drug product, and Medix will be responsible for its commercialization in the Mexican market.

The article originally appeared on Business Standard.

You May Also Like

World

A leader of Kataib Hezbollah and two of his guards were in a vehicle when it was targeted in the east of the Iraqi...

World

Pakistan will discuss an Extended Fund Facility (EFF) with the International Monetary Fund (IMF) in Washington next month, Finance Minister Muhammad Aurangzeb said on...

Business

New York CNN — Apple has received approval to change the way its smartwatches function so the company can overcome the Apple Watch ban imposed by...

Finance

NEW YORK – Gold prices saw a marginal increase today, with spot gold trading at $2,030.87 per ounce. The uptick in the precious metal’s value coincided...

Copyright © 2024 prwireonline

Exit mobile version